Advantages of the NeoTYPE® NGS Cancer Profiles include:
Breadth and focus: with three large pan-tumor Profiles and 25 targeted cancer-specific Profiles, NeoGenomics provides the widest variety of actionable tumor profiles suitable for every unique patient
Quantitative results: abnormal reports show percentage mutated gene vs. wild-type
Flexible level of service: FISH and most IHC components of NeoTYPE® Profiles may be ordered as Tech-Only or Global by pathology clients
Integrated reporting: comprehensive summary of results that includes diagnostic, prognostic, therapeutic and clinical trials information
Pharma ready: can be used in all phases of clinical trials and appropriate as a companion diagnostic
Highly focused molecular profiling with the NeoTYPE® Cancer-Specific Profiles delivers fast, actionable results
|AITL/Peripheral T-Cell Lymphoma||AML Prognostic||CLL Prognostic||JMML|
|GI Predictive||GIST/Soft Tissue||Head & Neck||HRD+ Profile|
|Other Solid Tumor||Ovarian||Pancreas||Thyroid|
NeoTYPE® Broad Reach Tumor Profiles for Heme & Solid Tumors
The National Cancer Institute (NCI) and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) co-developed the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) study (also known as study EAY131). NCI-MATCH is a large precision medicine cancer trial with nearly 40 treatment arms exploring numerous genetic abnormalities and drugs in a large number of rare and common cancer types.
NeoGenomics is one of the designated laboratories in the NCI-MATCH trial and provides 19 different NeoTYPE® Solid Tumor Profiles that may qualify a patient for the study. Learn more
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients